Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
May 24, 2023
What’s new in breast cancer research? SABCS 2022 delivers plenty
Studies highlight research on treatment toxicity, disparities in insurance, gaps in metastatic care, new therapies and more
What’s new in breast cancer research? SABCS20 goes virtual
Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more
Trio of studies to evaluate metastatic breast cancer care
Hutch researcher awarded grants to study the use of biopsy to drive therapy choices and test new type of PET scan to stage lobular
What's new in breast cancer research: #SABCS19 edition
Fred Hutch researchers share long-term follow-up data on WHI hormone study, anti-hormone side-effect strategies and more at San Antonio meeting
Metastatic breast cancer research takes the stage
Advocates, oncologists and researchers share findings, resources and reasons for hope at third annual NW Mets Conference
Lobular breast cancer comes into the research spotlight
Research collaborations, patient advocates push to explore ‘sneaky,’ understudied subtype’s standing as a distinct disease
Metastatic breast cancer patients gather in Seattle to talk research, cures
300 patients, advocates and researchers talk science, health disparities and filling in crucial data gaps at 'mets' conference
Understanding Rita Wilson's diagnosis
Oncologist Dr. V.K. Gadi explains the actress's type of breast cancer: lobular carcinoma in situ
Combined hormone therapy increases risk of lobular breast cancer fourfold after just three years of use
Fred Hutchinson Cancer Research Center leads first study designed to evaluate the association between combined HRT use and the risk of lobular breast cancers
Combined hormone therapy increases risk of lobular breast cancer fourfold after just three years of use
Center leads first study designed to evaluate the association between combined HRT use and the risk of lobular breast cancers